Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 19, Issue 12, Pages -Publisher
SPRINGER
DOI: 10.1007/s11864-018-0584-3
Keywords
Ovarian cancer; Immunotherapy; Immune checkpoint inhibitors; Cancer vaccine; Adoptive immunotherapy; PD1; PD-L1; PD-L2; CTLA-4; Nivolumab; Ipilimumab; Pembrolizumab; Avelumab; Atezolizumab; PARP inhibitors; BRCA 1; 2 mutation; Microsatellite instability; Bevacizumab; Anti-angiogenic; NY-ESO; MAGE; p53; Mirvetuximab soravtansine; Folate receptor alpha; Folate-binding protein; TILS; CAR-T cells; NK cells; T cells; HER2; Mesothelin
Categories
Ask authors/readers for more resources
Opinion statementThe rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term immunotherapy envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
